Why ZYNLONTA still matters for ADC Therapeutics in a tightening lymphoma market

ZYNLONTA steps into a crowded lymphoma ward where every extra month of control counts. The antibody-drug conjugate from ADC Therapeutics promises targeted power with an outpatient-friendly rhythm, but faces pressure from rivals and payer scrutiny.

Reviewed: ad hoc news Accessory & Components desk. Edited and checked on 2026-06-17, 09:52. Details in the imprint.

With ZYNLONTA, patients with relapsed or refractory diffuse large B-cell lymphoma sit in an infusion chair hoping that one more targeted option buys them time without wrecking their week. The antibody-drug conjugate aims for tumor cells with a payload that feels both focused and ruthless.

How ZYNLONTA is built

ZYNLONTA, also known as loncastuximab tesirine, is an antibody-drug conjugate that binds to CD19 on B cells and delivers a cytotoxic PBD-based payload directly into lymphoma cells.

The drug is given as an intravenous infusion in 21-day cycles, with a schedule designed to fit into outpatient oncology routines.

Position in lymphoma treatment

Regulators cleared ZYNLONTA for adults with relapsed or refractory diffuse large B-cell lymphoma after at least two prior lines of systemic therapy, giving physicians another option once standard regimens and CAR-T are exhausted.

In its pivotal LOTIS-2 trial, the medicine showed a confirmed overall response rate a little above 45 percent, with a subset of patients achieving complete responses that lasted several months.

What patients feel in practice

In everyday use, patients typically arrive at the infusion center for a relatively short drip rather than an all-day marathon, which many describe as physically and mentally easier than some earlier chemotherapy blocks.

However, the targeted payload is anything but gentle at the microscopic level, and hematologic toxicities such as neutropenia and thrombocytopenia remain a real burden that treating teams have to watch closely.

Side effects and management

Common side effects in trials included fatigue, infections, edema, and laboratory abnormalities, reflecting both the potency of the payload and the fragility of heavily pretreated patients.

Oncology centers often build ZYNLONTA into structured monitoring protocols, with regular blood counts and supportive treatments to keep patients on therapy when it works.

Pricing and market pressure

ZYNLONTA sits in a high-price oncology niche where payers scrutinize every new entrant and increasingly demand real-world data beyond trial curves to justify reimbursement.

At the same time, competition from other targeted agents and cellular therapies in relapsed DLBCL raises the bar for staying on formularies and securing favorable positioning.

Role for ADC Therapeutics and the stock

For ADC Therapeutics SA, ZYNLONTA is a central commercial asset that shapes cash flow expectations and underpins much of the company’s narrative on antibody-drug conjugates.

Shares of ADC Therapeutics SA (CH0498599052) are listed on the New York Stock Exchange under the ticker ADCT.

Key facts on ZYNLONTA

• Product: ZYNLONTA (loncastuximab tesirine)
• Manufacturer: ADC Therapeutics SA
• Category: Classic/Longseller
• Launch: US FDA accelerated approval in 2021 for relapsed or refractory DLBCL after at least two prior therapies
• RRP / Price: High-cost oncology therapy, contract-dependent and varying by market and payer
• Availability: Prescription oncology product, primarily via hospital and specialist hematology-oncology centers in approved markets
• Target group: Adult patients with relapsed or refractory diffuse large B-cell lymphoma after multiple prior lines
• Highlight / USP: Targeted CD19-directed ADC option for heavily pretreated DLBCL patients with an outpatient-friendly dosing schedule

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.